Implementation of PET/CT in radiation oncology-a patterns-of-care analysis of the German Society of Nuclear Medicine and the German Society of Radiation Oncology.
Germany
PET/CT
Planning PET
Reimbursement
Survey
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
09 Aug 2024
09 Aug 2024
Historique:
received:
25
02
2024
accepted:
23
06
2024
medline:
9
8
2024
pubmed:
9
8
2024
entrez:
9
8
2024
Statut:
aheadofprint
Résumé
The use of positron-emission tomography (PET)/computed tomography (CT) in radiation therapy (RT) has increased. Radiation oncologists (RadOncs) have access to PET/CT with a variety of tracers for different tumor entities and use it for target volume definition. The German Society of Nuclear Medicine (DGN) and the German Society of Radiation Oncology (DEGRO) aimed to identify current patterns of care in order to improve interdisciplinary collaboration. We created an online survey on participating RadOncs' use of PET tracers for different tumor entities and how they affect RT indication, dose prescription, and target volume definition. Further topics were reimbursement of PET/CT and organizational information (fixed timeslots and use of PET with an immobilization device [planning/RT-PET]). The survey contained 31 questions in German language (yes/no questions, multiple choice [MC] questions, multiple select [MS] questions, and free-text entry options). The survey was distributed twice via the DEGRO member mailing list. During the survey period (May 22-August 7, 2023) a total of 156 RadOncs (13% of respondents) answered the survey. Among these, 59% reported access to diagnostic PET/CT within their organization/clinic and 24% have fixed timeslots for their patients. 37% of survey participants can perform RT-PET and 29% have the option of providing a dedicated RT technician for planning PET. Besides [ This is the first nationwide survey on the role of PET/CT for RT planning among RadOncs in Germany. We find high acceptance of PET results for treatment decisions and target volume definition. Planning PET comes with logistic challenges for different healthcare settings (e.g., private practices vs. university hospitals). The decision to request PET/CT is often based on the possibility of reimbursement. PET/CT has become an important tool for RadOncs, with several indications. However, access is still limited at several sites, especially for dedicated RT-PET. This study aims to improve interdisciplinary cooperation and adequate implementation of current guidelines for the treatment of various tumor entities.
Sections du résumé
BACKGROUND
BACKGROUND
The use of positron-emission tomography (PET)/computed tomography (CT) in radiation therapy (RT) has increased. Radiation oncologists (RadOncs) have access to PET/CT with a variety of tracers for different tumor entities and use it for target volume definition. The German Society of Nuclear Medicine (DGN) and the German Society of Radiation Oncology (DEGRO) aimed to identify current patterns of care in order to improve interdisciplinary collaboration.
METHODS
METHODS
We created an online survey on participating RadOncs' use of PET tracers for different tumor entities and how they affect RT indication, dose prescription, and target volume definition. Further topics were reimbursement of PET/CT and organizational information (fixed timeslots and use of PET with an immobilization device [planning/RT-PET]). The survey contained 31 questions in German language (yes/no questions, multiple choice [MC] questions, multiple select [MS] questions, and free-text entry options). The survey was distributed twice via the DEGRO member mailing list.
RESULTS
RESULTS
During the survey period (May 22-August 7, 2023) a total of 156 RadOncs (13% of respondents) answered the survey. Among these, 59% reported access to diagnostic PET/CT within their organization/clinic and 24% have fixed timeslots for their patients. 37% of survey participants can perform RT-PET and 29% have the option of providing a dedicated RT technician for planning PET. Besides [
DISCUSSION
CONCLUSIONS
This is the first nationwide survey on the role of PET/CT for RT planning among RadOncs in Germany. We find high acceptance of PET results for treatment decisions and target volume definition. Planning PET comes with logistic challenges for different healthcare settings (e.g., private practices vs. university hospitals). The decision to request PET/CT is often based on the possibility of reimbursement.
CONCLUSION
CONCLUSIONS
PET/CT has become an important tool for RadOncs, with several indications. However, access is still limited at several sites, especially for dedicated RT-PET. This study aims to improve interdisciplinary cooperation and adequate implementation of current guidelines for the treatment of various tumor entities.
Identifiants
pubmed: 39120747
doi: 10.1007/s00066-024-02260-4
pii: 10.1007/s00066-024-02260-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Lapa C, Nestle U, Albert NL, Baues C, Beer A, Buck A et al (2021) Value of PET imaging for radiation therapy. Strahlenther Onkol 197:1–23. https://doi.org/10.1007/s00066-021-01812-2
doi: 10.1007/s00066-021-01812-2
pubmed: 34259912
Lapa C, Nestle U, Albert NL, Baues C, Beer A, Buck A et al (2021) Value of PET imaging for radiation therapy. Nuklearmedizin 60:326–343. https://doi.org/10.1055/a-1525-7029
doi: 10.1055/a-1525-7029
pubmed: 34261141
Nestle U, Schimek-Jasch T, Kremp S, Schaefer-Schuler A, Mix M, Kusters A et al (2020) Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. Lancet Oncol 21:581–592. https://doi.org/10.1016/S1470-2045(20)30013-9
doi: 10.1016/S1470-2045(20)30013-9
pubmed: 32171429
Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY et al (2019) Assessment of 68ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol 5:856–863. https://doi.org/10.1001/jamaoncol.2019.0096
doi: 10.1001/jamaoncol.2019.0096
pubmed: 30920593
pmcid: 6567829
Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P et al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395:1208–1216. https://doi.org/10.1016/S0140-6736(20)30314-7
doi: 10.1016/S0140-6736(20)30314-7
pubmed: 32209449
Grosu AL, Piert M, Weber WA, Jeremic B, Picchio M, Schratzenstaller U et al (2005) Positron emission tomography for radiation treatment planning. Strahlenther Onkol 181:483–499. https://doi.org/10.1007/s00066-005-1422-7
doi: 10.1007/s00066-005-1422-7
pubmed: 16044216
Ford EC, Herman J, Yorke E, Wahl RL (2009) 18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy. J Nucl Med 50:1655–1665. https://doi.org/10.2967/jnumed.108.055780
doi: 10.2967/jnumed.108.055780
pubmed: 19759099
International Atomic Energy Agency (2008) The role of PET/CT in radiation treatment planning for cancer patient treatment. IAEA-TECDOC, vol 1603. IAEA, Vienna
Richtlinie des Gemeinsamen Bundesausschusses zu Untersuchungs- und Behandlungsmethoden der vertragsärztlichen Versorgung (Richtlinie Methoden vertragsärztliche Versorgung) in der Fassung vom 17. Januar 2006 veröffentlicht im Bundesanzeiger Nr. 48 (S. 1523) vom 9. März 2006 in Kraft getreten am 1. April 2006 zuletzt geändert am 20. Oktober 2022 veröffentlicht im Bundesanzeiger (BAnz AT 13 Jan 2023 B3) in Kraft getreten am 14. Januar 2023.
Oehlke O, Mix M, Graf E, Schimek-Jasch T, Nestle U, Gotz I et al (2016) Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA)—protocol of a randomized phase II trial (NOA 10/ARO 2013-1). BMC Cancer 16:769. https://doi.org/10.1186/s12885-016-2806-z
doi: 10.1186/s12885-016-2806-z
pubmed: 27716184
pmcid: 5052714
Popp I, Bott S, Mix M, Oehlke O, Schimek-Jasch T, Nieder C et al (2019) Diffusion-weighted MRI and ADC versus FET-PET and GdT1w-MRI for gross tumor volume (GTV) delineation in re-irradiation of recurrent glioblastoma. Radiother Oncol 130:121–131. https://doi.org/10.1016/j.radonc.2018.08.019
doi: 10.1016/j.radonc.2018.08.019
pubmed: 30219612
Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA et al (2017) PET-guided treatment in patients with advanced-stage hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German hodgkin study group. Lancet 390:2790–2802. https://doi.org/10.1016/S0140-6736(17)32134-7
doi: 10.1016/S0140-6736(17)32134-7
pubmed: 29061295
Borchmann P, Plutschow A, Kobe C, Greil R, Meissner J, Topp MS et al (2021) PET-guided omission of radiotherapy in early-stage unfavourable hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 22:223–234. https://doi.org/10.1016/S1470-2045(20)30601-X
doi: 10.1016/S1470-2045(20)30601-X
pubmed: 33539742
Specht L, Yahalom J, Illidge T, Berthelsen AK, Constine LS, Eich HT et al (2014) Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys 89:854–862. https://doi.org/10.1016/j.ijrobp.2013.05.005
doi: 10.1016/j.ijrobp.2013.05.005
pubmed: 23790512
Ferdinandus J, van Heek L, Roth K, Dietlein M, Eich HT, Baues C et al (2023) Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage hodgkin’s lymphoma: an analysis of the randomized phase III HD18 trial by the German hodgkin study group. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-023-06431-w
doi: 10.1007/s00259-023-06431-w
pubmed: 37735258
pmcid: 10774157
Ferdinandus J, Muller H, Damaschin C, Jacob AS, Meissner J, Krasniqi F et al (2023) Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced stage hodgkin lymphoma: results from the randomized international GHSG HD18 trial. Ann Oncol. https://doi.org/10.1016/j.annonc.2023.11.014
doi: 10.1016/j.annonc.2023.11.014
pubmed: 38061428
Grosu AL, Weber WA, Astner ST, Adam M, Krause BJ, Schwaiger M et al (2006) 11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 66:339–344. https://doi.org/10.1016/j.ijrobp.2006.02.047
doi: 10.1016/j.ijrobp.2006.02.047
pubmed: 16765533
Vogel MME, Dewes S, Sage EK, Devecka M, Gschwend JE, Eiber M et al (2021) A survey among German-speaking radiation oncologists on PET-based radiotherapy of prostate cancer. Radiat Oncol 16:82. https://doi.org/10.1186/s13014-021-01811-8
doi: 10.1186/s13014-021-01811-8
pubmed: 33933111
pmcid: 8088662
Frenzel T, Tienken M, Abel M, Berliner C, Klutmann S, Beyersdorff D et al (2018) The impact of [(68)Ga]PSMA I&T PET/CT on radiotherapy planning in patients with prostate cancer. Strahlenther Onkol 194:646–654. https://doi.org/10.1007/s00066-018-1291-5
doi: 10.1007/s00066-018-1291-5
pubmed: 29572670
Alberto M, Yim A, Papa N, Siva S, Ischia J, Touijer K et al (2022) Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer. Front Oncol 12:929444. https://doi.org/10.3389/fonc.2022.929444
doi: 10.3389/fonc.2022.929444
pubmed: 36059632
pmcid: 9433573
Schmidt-Hegemann NS, Eze C, Li M, Rogowski P, Schaefer C, Stief C et al (2019) Impact of (68)ga-PSMA PET/CT on the radiotherapeutic approach to prostate cancer in comparison to CT: a retrospective analysis. J Nucl Med 60:963–970. https://doi.org/10.2967/jnumed.118.220855
doi: 10.2967/jnumed.118.220855
pubmed: 30552203
pmcid: 6604695
Schmidt-Hegemann NS, Fendler WP, Ilhan H, Herlemann A, Buchner A, Stief C et al (2018) Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy. Radiat Oncol 13:37. https://doi.org/10.1186/s13014-018-0983-4
doi: 10.1186/s13014-018-0983-4
pubmed: 29499730
pmcid: 5833127
Holzgreve A, Unterrainer M, Calais J, Adams T, Oprea-Lager DE, Goffin K et al (2023) Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial. Eur J Nucl Med Mol Imaging 50:3750–3754. https://doi.org/10.1007/s00259-023-06332-y
doi: 10.1007/s00259-023-06332-y
pubmed: 37428216
pmcid: 10547650
Zamboglou C, Peeken JC, Janbain A, Katsahian S, Strouthos I, Ferentinos K et al (2023) Development and validation of a multi-institutional nomogram of outcomes for PSMA-PET-based salvage radiotherapy for recurrent prostate cancer. JAMA Netw Open 6:e2314748. https://doi.org/10.1001/jamanetworkopen.2023.14748
doi: 10.1001/jamanetworkopen.2023.14748
pubmed: 37219907
pmcid: 10208140
Zamboglou C, Spohn SKB, Adebahr S, Huber M, Kirste S, Sprave T et al (2021) PSMA-PET/MRI-based focal dose escalation in patients with primary prostate cancer treated with stereotactic body radiation therapy (hypofocal-SBRT): study protocol of a randomized, multicentric phase III trial. Cancers. https://doi.org/10.3390/cancers13225795
doi: 10.3390/cancers13225795
pubmed: 34830950
pmcid: 8616152
Wegen S, Weindler J, Voltin CA, van Heek L, Schomacker K, Fischer T et al (2023) Dual-tracer PET/CT protocol with [(18)F]FDG and [(68)Ga]Ga-FAPI-46 outperforms single-tracer PET/CT with [(18)F]FDG in different cancer types, resulting in larger functional and gross tumor volume. Strahlenther Onkol. https://doi.org/10.1007/s00066-023-02117-2
doi: 10.1007/s00066-023-02117-2
pubmed: 37975882
pmcid: 11111518
Syed M, Flechsig P, Liermann J, Windisch P, Staudinger F, Akbaba S et al (2020) Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers. Eur J Nucl Med Mol Imaging 47:2836–2845. https://doi.org/10.1007/s00259-020-04859-y
doi: 10.1007/s00259-020-04859-y
pubmed: 32447444
pmcid: 7567680
Guberina N, Kessler L, Pottgen C, Guberina M, Metzenmacher M, Herrmann K et al (2022) (68)Ga]FAPI-PET/CT for radiation therapy planning in biliary tract, pancreatic ductal adeno-, and adenoidcystic carcinomas. Sci Rep 12:16261. https://doi.org/10.1038/s41598-022-20447-6
doi: 10.1038/s41598-022-20447-6
pubmed: 36171444
pmcid: 9519639
Koerber SA, Rohrich M, Walkenbach L, Liermann J, Choyke PL, Fink C et al (2023) Impact of (68)ga-FAPI PET/CT on staging and oncologic management in a cohort of 226 patients with various cancers. J Nucl Med 64:1712–1720. https://doi.org/10.2967/jnumed.123.266046
doi: 10.2967/jnumed.123.266046
pubmed: 37678928
pmcid: 10626373
Wegen S, van Heek L, Linde P, Claus K, Akuamoa-Boateng D, Baues C et al (2022) Head-to-head comparison of [(68) ga]ga-FAPI-46-PET/CT and [(18)F]F-FDG-PET/CT for radiotherapy planning in head and neck cancer. Mol Imaging Biol 24:986–994. https://doi.org/10.1007/s11307-022-01749-7
doi: 10.1007/s11307-022-01749-7
pubmed: 35771317
pmcid: 9681697
Liermann J, Syed M, Ben-Josef E, Schubert K, Schlampp I, Sprengel SD et al (2021) Impact of FAPI-PET/CT on target volume definition in radiation therapy of locally recurrent pancreatic cancer. Cancers. https://doi.org/10.3390/cancers13040796
doi: 10.3390/cancers13040796
pubmed: 33672893
pmcid: 7918160
Coffey M, Vaandering A (2010) Patient setup for PET/CT acquisition in radiotherapy planning. Radiother Oncol 96:298–301. https://doi.org/10.1016/j.radonc.2010.07.020
doi: 10.1016/j.radonc.2010.07.020
pubmed: 20727605
Hwang AB, Bacharach SL, Yom SS, Weinberg VK, Quivey JM, Franc BL et al (2009) Can positron emission tomography (PET) or PET/computed tomography (CT) acquired in a nontreatment position be accurately registered to a head-and-neck radiotherapy planning CT? Int J Radiat Oncol Biol Phys 73:578–584. https://doi.org/10.1016/j.ijrobp.2008.09.041
doi: 10.1016/j.ijrobp.2008.09.041
pubmed: 19084350
Wegen S, Roth KS, Weindler J, Claus K, Linde P, Trommer M et al (2023) First clinical experience with [68ga]ga-FAPI-46-PET/CT versus [18F]F-FDG PET/CT for nodal staging in cervical cancer. Clin Nucl Med 48:150–155. https://doi.org/10.1097/RLU.0000000000004505
doi: 10.1097/RLU.0000000000004505
pubmed: 36607364
Heeren PA, Jager PL, Bongaerts F, van Dullemen H, Sluiter W, Plukker JT (2004) Detection of distant metastases in esophageal cancer with (18)F-FDG PET. J Nucl Med 45:980–987
pubmed: 15181133
Goel R, Moore W, Sumer B, Khan S, Sher D, Subramaniam RM (2017) Clinical practice in PET/CT for the management of head and neck squamous cell cancer. AJR Am J Roentgenol 209:289–303. https://doi.org/10.2214/AJR.17.18301
doi: 10.2214/AJR.17.18301
pubmed: 28731808